GOLGA6L2: A Potential Drug Target for Cancer and Testicular Diseases

Target Name: GOLGA6L2

NCBI ID: G283685

GOLGA6L2

GOLGA6L2: A Potential Drug Target for Cancer and Testicular Diseases

GOLGA6L2 (Cancer/testis antigen 105) is a protein that is expressed in a variety of tissues, including the brain, testes, and gastrointestinal tract. It is also a potential drug target for cancer and testicular diseases.

GOLGA6L2 is a member of the GOLGA family, which is known for its role in intracellular signaling. The GOLGA family is characterized by the presence of a unique transmembrane domain, a cytoplasmic tail, and a N-end rule signal (NES) in the extracellular domain. GOLGA6L2 is a 21-kDa protein that consists of a 191 amino acid residue.

GOLGA6L2 is expressed in a variety of tissues, including the brain, testes, and gastrointestinal tract. It is highly expressed in the testes, with levels up to 10 times higher than in other tissues. This high expression level in the testes makes GOLGA6L2 an attractive drug target for testicular diseases.

In addition to its expression in the testes, GOLGA6L2 is also expressed in other tissues that are susceptible to cancer. For example, it is highly expressed in the lungs, colon, and prostate, and has been used as a biomarker for various types of cancer, including lung, breast, and prostate cancer.

GOLGA6L2's potential as a drug target is based on its unique structure and its expression in a variety of tissues. Its N-end rule signal is a potential target for small molecules that can modulate its activity. Additionally, its cytoplasmic tail and transmembrane domain suggest that it may have a role in intracellular signaling pathways.

GOLGA6L2 has also been shown to play a role in several diseases, including cancer and testicular dysgenesis syndrome (TDS). TDS is a genetic disorder that affects the development and function of testicular tissue, including germ cells and the urogenital tract. The exact cause of TDS is not known, but it is often associated with mutations in genes that are involved in cell signaling pathways.

One of the challenges in targeting GOLGA6L2 as a drug is its widespread expression in a variety of tissues, making it difficult to predict its effectiveness. Additionally, its role in multiple diseases makes it difficult to identify a specific target for therapy.

Despite these challenges, research into GOLGA6L2 is ongoing. Researchers are using various techniques, including RNA interference, to identify potential small molecules that can modulate its activity. Additionally, researchers are using techniques such as mass spectrometry to identify potential binding partners for its N-end rule signal.

In conclusion, GOLGA6L2 is a protein that is expressed in a variety of tissues and has been identified as a potential drug target for cancer and testicular diseases. Its unique structure and its expression in multiple tissues make it an attractive target for small molecules that can modulate its activity. Further research is needed to determine its effectiveness as a drug and to identify potential strategies for targeting it in the treatment of cancer and testicular diseases.

Protein Name: Golgin A6 Family Like 2

The "GOLGA6L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GOLGA6L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets